Plain-English translation of NCT07451002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostatic Neoplasms research guide →This is an observational study following men with metastatic hormone-sensitive prostate cancer who are being treated with apalutamide. Rather than testing a new drug, researchers want to understand how well patients stick with taking this medication as prescribed, and what factors might make it harder or easier for people to stay consistent with their treatment over time.
Taking cancer medications exactly as prescribed is crucial for the best outcomes, but many patients struggle with this in real life. This study aims to identify the challenges people face so doctors can better support patients and improve their chances of success with this medication.
You likely qualify if…
You likely don't qualify if…
You would visit your cancer doctor for routine appointments over 12 months while taking the medication as prescribed. At the beginning and throughout the year, you would complete short questionnaires about how you're managing with the medication and how you're feeling. The study simply tracks your real-world experience — no extra tests or procedures are required beyond your normal cancer care.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
France
Sponsor
Janssen Cilag S.A.S.
Enrollment target
~540 participants
Started
December 2025
Primary completion
January 2028
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Contact
Janssen-Cilag France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.